Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245991213> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4245991213 abstract "Abstract Background: The HER2 extracellular domain shed in blood (HER2 ECD ) is reported to rise and fall in parallel with HER2+ breast cancer behavior. In this study, we evaluated the clinical relevance of plasma HER2 ECD values in patients with metastatic breast cancer treated in the SAKK22/99 trial comparing trastuzumab monotherapy followed by trastuzumab-chemotherapy combination at progression versus upfront combination therapy. Methods : Quantitative assessment of plasma HER2 ECD was performed in 133 patients at baseline; after 2-24 hours; at 3 weeks; at first response evaluation (8-9 weeks); and at tumor progression. Associations with tumor characteristics, disease course and trial treatment were evaluated. Results: Baseline HER2 ECD levels were stable within 24 hours after the first trastuzumab injection. These plasma values correlated positively with the HER2 gene ratio (r s =0.39, P <0.001) and HER2 protein expression levels (r s =0.36, P <0.001) but not with ER/PR status of the primary tumor. HER2 ECD baseline levels were positively associated with the presence of visceral disease ( P =0.05) and poor patients’ outcome (Cox-regression: P =0.009). Patients with high baseline levels ( > 35ng/ml) had the worst overall survival ( P =0.03) if treated with upfront combination therapy. Conversely, patients with low HER2 ECD baseline values (<15ng/ml) had longer time to progression on combined trastuzumab-chemotherapy when first treated with trastuzumab monotherapy ( P =0.02). Monitoring HER2 ECD levels during the course of the trial revealed significant time ( P =0.001) and time-treatment arm interactions ( P =0.0007). Under upfront trastuzumab alone, the HER2 ECD levels remained stable until just before disease progression. In patients responding to combination treatment HER2 ECD levels decreased to > 20%. Conclusions: Plasma HER2 ECD levels in patients with metastatic breast cancer reflect HER2 disease status. This robust biomarker might help identifying patients without visceral disease profiting from a sequential treatment’s modality. Monitoring HER2 ECD levels during trastuzumab monotherapy could help defining the optimal time to introduce chemotherapy." @default.
- W4245991213 created "2022-05-12" @default.
- W4245991213 creator A5006229315 @default.
- W4245991213 creator A5031581462 @default.
- W4245991213 creator A5031592069 @default.
- W4245991213 creator A5044589331 @default.
- W4245991213 creator A5061473697 @default.
- W4245991213 creator A5061698687 @default.
- W4245991213 creator A5065813790 @default.
- W4245991213 creator A5070351685 @default.
- W4245991213 date "2020-01-22" @default.
- W4245991213 modified "2023-10-16" @default.
- W4245991213 title "Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: Results of a randomized study - SAKK 22/99." @default.
- W4245991213 cites W1763604934 @default.
- W4245991213 cites W1971481885 @default.
- W4245991213 cites W1986291899 @default.
- W4245991213 cites W1987380783 @default.
- W4245991213 cites W1988610380 @default.
- W4245991213 cites W2024032315 @default.
- W4245991213 cites W2024896551 @default.
- W4245991213 cites W2075075174 @default.
- W4245991213 cites W2077778212 @default.
- W4245991213 cites W2087868278 @default.
- W4245991213 cites W2096205264 @default.
- W4245991213 cites W2097255042 @default.
- W4245991213 cites W2099117820 @default.
- W4245991213 cites W2128179232 @default.
- W4245991213 cites W2154655712 @default.
- W4245991213 cites W2163873687 @default.
- W4245991213 cites W2168953808 @default.
- W4245991213 cites W2567078974 @default.
- W4245991213 cites W2792392509 @default.
- W4245991213 cites W2889232066 @default.
- W4245991213 cites W2904225773 @default.
- W4245991213 doi "https://doi.org/10.21203/rs.2.11084/v3" @default.
- W4245991213 hasPublicationYear "2020" @default.
- W4245991213 type Work @default.
- W4245991213 citedByCount "0" @default.
- W4245991213 crossrefType "posted-content" @default.
- W4245991213 hasAuthorship W4245991213A5006229315 @default.
- W4245991213 hasAuthorship W4245991213A5031581462 @default.
- W4245991213 hasAuthorship W4245991213A5031592069 @default.
- W4245991213 hasAuthorship W4245991213A5044589331 @default.
- W4245991213 hasAuthorship W4245991213A5061473697 @default.
- W4245991213 hasAuthorship W4245991213A5061698687 @default.
- W4245991213 hasAuthorship W4245991213A5065813790 @default.
- W4245991213 hasAuthorship W4245991213A5070351685 @default.
- W4245991213 hasBestOaLocation W42459912131 @default.
- W4245991213 hasConcept C121608353 @default.
- W4245991213 hasConcept C126322002 @default.
- W4245991213 hasConcept C143998085 @default.
- W4245991213 hasConcept C2775930923 @default.
- W4245991213 hasConcept C2776694085 @default.
- W4245991213 hasConcept C2779786085 @default.
- W4245991213 hasConcept C50382708 @default.
- W4245991213 hasConcept C530470458 @default.
- W4245991213 hasConcept C71924100 @default.
- W4245991213 hasConceptScore W4245991213C121608353 @default.
- W4245991213 hasConceptScore W4245991213C126322002 @default.
- W4245991213 hasConceptScore W4245991213C143998085 @default.
- W4245991213 hasConceptScore W4245991213C2775930923 @default.
- W4245991213 hasConceptScore W4245991213C2776694085 @default.
- W4245991213 hasConceptScore W4245991213C2779786085 @default.
- W4245991213 hasConceptScore W4245991213C50382708 @default.
- W4245991213 hasConceptScore W4245991213C530470458 @default.
- W4245991213 hasConceptScore W4245991213C71924100 @default.
- W4245991213 hasLocation W42459912131 @default.
- W4245991213 hasLocation W42459912132 @default.
- W4245991213 hasLocation W42459912133 @default.
- W4245991213 hasOpenAccess W4245991213 @default.
- W4245991213 hasPrimaryLocation W42459912131 @default.
- W4245991213 hasRelatedWork W2023654245 @default.
- W4245991213 hasRelatedWork W2030434439 @default.
- W4245991213 hasRelatedWork W2050439103 @default.
- W4245991213 hasRelatedWork W2069175206 @default.
- W4245991213 hasRelatedWork W2092771806 @default.
- W4245991213 hasRelatedWork W2143625559 @default.
- W4245991213 hasRelatedWork W2218005127 @default.
- W4245991213 hasRelatedWork W2782589310 @default.
- W4245991213 hasRelatedWork W2937445726 @default.
- W4245991213 hasRelatedWork W2969515167 @default.
- W4245991213 isParatext "false" @default.
- W4245991213 isRetracted "false" @default.
- W4245991213 workType "article" @default.